文献速递膀胱癌与上尿路尿路上皮癌

膀胱内卡巴他赛、吉西他滨和顺铂治疗BCG无反应高危非肌层浸润性膀胱癌的2期试验

A Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Nonmuscle-Invasive Bacillus Calmette-Guérin-Unresponsive Urothelial Carcinoma of the Bladder.
PubMed 文献 · J Urol · 2026-07-17

这项单中心2期试验纳入33例BCG无反应高危非肌层浸润性膀胱癌患者,接受6周膀胱内卡巴他赛、吉西他滨和顺铂诱导治疗。12个月无复发生存率为73%(95%CI 57%-87%),24个月为59%(95%CI 42%-76%)。联合方案安全耐受,无剂量限制性毒性。

要点

  • 3个月无复发生存率82%,12个月73%,24个月59%
  • 无剂量限制性毒性,方案安全耐受
  • 结果可能优于许多其他非手术治疗

核心结论

  • 膀胱内卡巴他赛、吉西他滨和顺铂联合方案安全耐受,无复发生存结果优秀,可能优于许多其他非手术治疗。

研究设计与样本

  • 单中心2期试验,纳入33例BCG无反应高危非肌层浸润性膀胱癌患者,中位年龄72岁,中位随访30.8个月。

主要发现

  • 3个月无复发生存率为82%(95%CI 69%-95%),12个月为73%(95%CI 57%-87%),24个月为59%(95%CI 42%-76%)。
  • 24个月无复发生存限制平均生存时间估计为18.1个月(95%CI 15-21个月)。
  • 无剂量限制性毒性。

临床怎么用

  • 对于拒绝或不适合根治性膀胱切除术的BCG无反应高危非肌层浸润性膀胱癌患者,可考虑该联合膀胱内灌注方案。

局限性

  • 单中心、样本量较小(33例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A previously reported phase 1 trial at our institution using sequential instillation of intravesical cabazitaxel, gemcitabine, and cisplatin for bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer was found to be well tolerated and safe. Here we present our phase 2 results using this treatment protocol. MATERIALS AND METHODS: In this single-center trial, patients with BCG-unresponsive high-risk nonmuscle-invasive bladder cancer who refused or were ineligible for radical cystectomy received a 6-week intravesical induction course of cabazitaxel and gemcitabine weekly and cisplatin biweekly. Initial clinical response was defined as no evidence of high-grade disease on postinduction cystoscopy with biopsy at 3 months. Responders received maintenance therapy monthly with cabazitaxel and gemcitabine during the first year, and bimonthly for the second year, for a total of 24 months. Flexible cystoscopy was performed every 3 months, and any abnormalities prompted rigid cystoscopy and biopsy. Primary study outcome was recurrence-free survival (RFS) at 12 months. RESULTS: Thirty-three (33) patients were enrolled, of whom 7 were female. The median age was 72 years, and median follow-up was 30.8 months. At enrollment, all patients had high-grade disease and met the criteria for BCG-unresponsive disease. There were no dose-limiting toxicities. RFS at 3 months was 82% (95% CI 69%-95%), decreasing to 73% (95% CI 57%-87%) at 12 months, and 59% (95% CI 42%-76%) at 24 months. Restricted mean survival time for RFS at 24 months was estimated to be 18.1 months (95% CI 15-21 months). There were no dose-limiting toxicities. CONCLUSIONS: Combination intravesical cabazitaxel, gemcitabine, and cisplatin is safe and well tolerated. Recurrence-free survival results are excellent and may represent an improvement from many other available nonsurgical treatments for BCG-unresponsive bladder cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. DeCastro GJ, Joffe BI, Stein MN, et al. A Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Nonmuscle-Invasive Bacillus Calmette-Guérin-Unresponsive Urothelial Carcinoma of the Bladder. J Urol. 2026. PMID: 42467648. doi:10.1097/JU.0000000000005224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。